Literature DB >> 9622696

Subacute measles encephalitis with AIDS diagnosed by fine needle aspiration biopsy. A case report.

T P Poon1, V Tchertkoff, H Win.   

Abstract

BACKGROUND: Subacute measles encephalitis (SME), or measles inclusion body encephalitis (MIBE), is a rare central nervous system (CNS) complication following infection by the measles (rubeola) virus. It usually occurs in young patients with defective cellular immunity from either congenital or acquired causes. In the United States, with the resurgence of measles infection and the human immunodeficiency virus (HIV) pandemic, subacute measles encephalitis should be added to the differential diagnosis in acquired immune deficiency syndrome (AIDS) patients presenting with unexplained CNS manifestations. CASE: A 2-year-old, HIV-positive, white male was admitted for generalized convulsive seizures. Vaccination was described as "up to date." Despite treatment with anticonvulsive drugs, the child continued to develop frequent partial and generalized seizures. Cephalic computed tomography and magnetic resonance imaging revealed a hypodense area in the right parietotemporal cortex without an associated mass effect. Fine needle aspiration biopsy (FNAB) of the affected area showed neuronal reduction, degeneration with eosinophilic intranuclear inclusions, perivascular lymphoplasmacytic infiltration and gliosis. Electron microscopy of the intranuclear inclusions revealed fine, fibrillar, tubular nucleocapsids, consistent with the measles virus.
CONCLUSION: Acute measles encephalitis (AME), subacute sclerosing panencephalitis (SSPE), and SME are the three CNS syndromes associated with measles infection. Serum and cerebrospinal fluid (CSF) antibody titres against measles virus are usually high and helpful in the diagnosis of AME and SSPE. In SME, neither serum nor CSF antibody titres against measles are high. Therefore, FNAB is necessary for a definitive diagnosis.

Entities:  

Mesh:

Year:  1998        PMID: 9622696     DOI: 10.1159/000331835

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  8 in total

1.  Assessment of white matter damage in subacute sclerosing panencephalitis using quantitative diffusion tensor MR imaging.

Authors:  R Trivedi; R K Gupta; A Agarawal; K M Hasan; A Gupta; K N Prasad; G Bayu; D Rathore; R K S Rathore; P A Narayana
Journal:  AJNR Am J Neuroradiol       Date:  2006-09       Impact factor: 3.825

2.  Correlation of quantitative diffusion tensor tractography with clinical grades of subacute sclerosing panencephalitis.

Authors:  R Trivedi; H Anuradha; A Agarwal; R K S Rathore; K N Prasad; R P Tripathi; R K Gupta
Journal:  AJNR Am J Neuroradiol       Date:  2011-02-17       Impact factor: 3.825

3.  Productive measles virus brain infection and apoptosis in CD46 transgenic mice.

Authors:  A Evlashev; E Moyse; H Valentin; O Azocar; M C Trescol-Biémont; J C Marie; C Rabourdin-Combe; B Horvat
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  High pathogenicity of wild-type measles virus infection in CD150 (SLAM) transgenic mice.

Authors:  Caroline I Sellin; Nathalie Davoust; Vanessa Guillaume; Dominique Baas; Marie-Françoise Belin; Robin Buckland; T Fabian Wild; Branka Horvat
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 5.  Emerging diseases: measles.

Authors:  Martin O Ota; William J Moss; Diane E Griffin
Journal:  J Neurovirol       Date:  2005-10       Impact factor: 2.643

6.  A 16-year old male with cortical blindness and focal motor seizures.

Authors:  S M Katrak; A Mahadevan; Arun B Taly; S Sinha; S K Shankar
Journal:  Ann Indian Acad Neurol       Date:  2010-07       Impact factor: 1.383

Review 7.  Blue moon neurovirology: the merits of studying rare CNS diseases of viral origin.

Authors:  Lauren A O'Donnell; Glenn F Rall
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-24       Impact factor: 7.285

Review 8.  Neurological Complications of Measles (Rubeola).

Authors:  Marc C Patterson
Journal:  Curr Neurol Neurosci Rep       Date:  2020-02-07       Impact factor: 6.030

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.